USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Sequencing Solutions, Inc.

USPTO PatentsView assignee record - 273 granted patents across 40 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Roche ranks #1,528 of 49,997 tracked US assignees by granted-patent volume, with 273 patents across 40 technology areas.

#1,528
of 49,997 US assignees by volume
Top 4%
by Innovation Score (59.5/100)
15.1
avg claims per patent
+1079%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1528 · US Corporation #1,528 · 273 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 273 grants
  • TOP-DECILE #1,528/49,997
  • PHOTO-FINISH Nabtesco
  • CPC-WIDE C12Q · 40 areas
  • INNOV-PAR 59.5/100
  • CLAIMS-RICH 15.1 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +1079% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nabtesco Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Roche

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Roche's Innovation Score is 59.5/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Roche's grants concentrate

Roche Sequencing Solutions, Inc. is a focused PatentsView assignee: 40 CPC subclasses with 77.7% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2023 (54 grants) versus a trough of 1 in 2017. By volume, Roche sits between Nabtesco Corporation and China University of Mining and Technology.

Roche's three-year grant acceleration

From 2019–2021 to 2022–2024, Roche Sequencing Solutions, Inc. moved from 104 to 135 grants (1.30x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #642. See the growth leaderboard.

Who files at Roche's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Roche holds 273 patents at rank #1,528, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Roche

By rank, the assignees closest to #1,528 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Roche's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Roche, neither rank-band nor same-CPC leaders (those blocks stay above).

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0204060 201720182019202020212022202320242025 30
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Roche Sequencing Solutions, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 0.4%
2018 3 1.1%
2019 15 5.5%
2020 39 14.3%
2021 50 18.3%
2022 31 11.4%
2023 54 19.8%
2024 50 18.3%
2025partial year 30 11.0%

Which technologies does Roche Sequencing Solutions, Inc. patent most?

Top 15 of 40 technology areas

Where it ranks

Overall rank by patents

#1,528

of 49,997 tracked assignees

Innovation Score

59.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Roche Sequencing Solutions, Inc.'s patent record in context - here's where to go next.

  • Roche Sequencing Solutions, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 77.7% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #1,528 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Roche Sequencing Solutions, Inc. against Nabtesco Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 59.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.